📝 Indo Us Biotech Limited — results explained
Quarter ended December 2025 (Q3 FY26)
Indo Us Biotech Limited reported revenue of ₹23 crore for the quarter ended December 2025 (Q3 FY26).
Net profit stood at ₹3 crore. Earnings per share (EPS) came in at ₹1.49.
Operating profit stood at ₹4 crore — an operating margin (OPM) of 18.2%.
Valuation snapshot
At the current price of ₹71.95, INDOUS has a market capitalisation of ₹144 crore.
Within the Other Agricultural Products industry, it is the 19th-largest of the 59 companies we track by market value.
Shareholding pattern
As of Sep 2026, promoters held 68.29%, foreign institutional investors (FIIs) 0.01%, public shareholders 31.45%, domestic institutional investors (DIIs) 0.25% of Indo Us Biotech Limited.